Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Pietrantonio

Showing results (161-170 of 323) with videos related to

Pageof 33
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 21, 2021
Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancerGiovanni Randon, Rossana Intini, Chiara Cremolini, et al.
Cancer Treatment Reviews|January 11, 2022
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literaturePasquale Lombardi, Daniele Rossini, Veronica Crespi, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancerVincenzo Nasca, Francesco Barretta, Francesca Corti, et al.
Journal for Immunotherapy of Cancer|April 21, 2023
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE studyRoberto Moretto, Daniele Rossini, Aurélie Catteau, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2025
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studiesR Moretto, D Rossini, Mariam Grazia Polito, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 21, 2024
The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitorsFilippo Ghelardi, Giovanni Fucà, Chiara Cavalli, et al.
British Journal of Cancer|October 7, 2020
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONODaniele Rossini, Sara Lonardi, Carlotta Antoniotti, et al.
JCO Precision Oncology|April 18, 2025
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal CancerRoberto Moretto, Marco Maria Germani, Martina Carullo, et al.
Journal for Immunotherapy of Cancer|January 4, 2025
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitorsJulien Taieb, Margherita Ambrosini, Emily Alouani, et al.
Therapeutic Advances in Medical Oncology|January 8, 2025
Prognostic impact of depth of response and early tumour shrinkage in patients with <i>BRAF</i> <sup></sup> -mutated metastatic colorectal cancer treated with targeted therapyGuglielmo Vetere, Marco Maria Germani, Carlotta Antoniotti, et al.
Pageof 33

Showing results (161-170 of 323) with videos related to

Sort By:
Pageof 33
European Journal of Cancer (Oxford, England : 1990)|December 21, 2021
Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancerGiovanni Randon, Rossana Intini, Chiara Cremolini, et al.
Cancer Treatment Reviews|January 11, 2022
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literaturePasquale Lombardi, Daniele Rossini, Veronica Crespi, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancerVincenzo Nasca, Francesco Barretta, Francesca Corti, et al.
Journal for Immunotherapy of Cancer|April 21, 2023
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE studyRoberto Moretto, Daniele Rossini, Aurélie Catteau, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2025
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studiesR Moretto, D Rossini, Mariam Grazia Polito, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 21, 2024
The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitorsFilippo Ghelardi, Giovanni Fucà, Chiara Cavalli, et al.
British Journal of Cancer|October 7, 2020
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONODaniele Rossini, Sara Lonardi, Carlotta Antoniotti, et al.
JCO Precision Oncology|April 18, 2025
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal CancerRoberto Moretto, Marco Maria Germani, Martina Carullo, et al.
Journal for Immunotherapy of Cancer|January 4, 2025
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitorsJulien Taieb, Margherita Ambrosini, Emily Alouani, et al.
Therapeutic Advances in Medical Oncology|January 8, 2025
Prognostic impact of depth of response and early tumour shrinkage in patients with <i>BRAF</i> <sup></sup> -mutated metastatic colorectal cancer treated with targeted therapyGuglielmo Vetere, Marco Maria Germani, Carlotta Antoniotti, et al.
Pageof 33